A Phase 1b Study of OMP-305B83 Plus FOLFIRI as Second Line Therapy in Subjects With Metastatic Colorectal Cancer

Trial Profile

A Phase 1b Study of OMP-305B83 Plus FOLFIRI as Second Line Therapy in Subjects With Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Navicixizumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jan 2017 According to an OncoMed Pharmaceuticals media release, company announced the dosing of the first patient in this trial.
    • 04 Jan 2017 Status changed from planning to recruiting, as per an OncoMed Pharmaceuticals media release.
    • 10 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top